Kornimate/medical-research-clean huggingface dataset:
exploring the relationship between alpha-synucleinopathy related non-motor symptom and post-op. delirium in elderly patients with spine surgery

Conditions: Post-operation Delirium; Alpha-synucleinopathy Related Non-motor Symptom

Summary: hypothesis is that the presence of a-synucleinopathy related non motor symptoms could be predictive factor for post-operative delirium. during 72hrs after spine surgery, investigator will observe occurrence of post-operative delirium, and analysis difference of a-synucleinopathy related non motor symptoms between 2 groups.

postoperative delirium appear approximately 10-70% of patients older than 65 yrs undergoing surgery and it is strongly associated with poor surgical outcome. the clinical characteristics of postoperative delirium are fluctuating attention, visual hallucination, disorganized thought and alter sleep-wake cycles. this is quite similar to core features of α-synuclein-related cognitive disorders such as parkinson's disease dementia and dementia with lewy body. at that point, investigator thought that postoperative delirium is preclinical stage of a-synucleinopathy. in other words, a-synuclein related disorders and postoperative delirium may share an underlying neurochemical change in their pathogenesis. investigator will recruit age 65 and older patients scheduled to perform spine surgery. the pre-operative evaluation include neurologic exam, baseline cognitive function and a-synucleinopathy related non motor symptoms through questionnaires.

Eligibility criteria:
inclusion criteria: 1. age 65 and older patients 2. scheduled to perform spine surgery in severance hospital exclusion criteria: 1. previous delirium history 2. previous chemotherapy or radiotherapy within 1yr due to underlying cancer. 3. severe hepatic/renal dysfunction

Keywords: delirium alpha synucleinopathy spine surgery
effects of wellnara on climacteric symptoms

Conditions: Postmenopause

Summary: aim of this nis is to obtain further information on efficacy, tolerability, and acceptance of wellnara in a large user population under the conditions of routine medical practice. furthermore, any adverse drug reactions will be recorded in a large user population under the conditions of medical routine. to investigate the efficacy of wellnara, patients will fill in a questionnaire, the so-called menopause rating scale (mrs ii). further, the effects of treatment on skin and hair will be evaluated by the investigator. patients will assess treatment effects on their sexual life. safety parameters include monitoring of vaginal bleeding, measurement of blood pressure and body weight, and - as far as routinely used in the practice - calculation of waist-hip-ratio. any relevant additional information related to adverse drug reactions will also be documented.


Eligibility criteria:
inclusion criteria: * women who have received a prescription of wellnara on the basis of the decision of the treating gynecologist exclusion criteria: * limited to the criteria listed in the expert information as contraindications

Keywords: climacteric symptoms
novel strategies for reducing burn scar itch

Conditions: Burn Scar; Itch Scarring; Wound

Summary: the purpose of the study is to see whether using diphenhydramine (benadryl), famotidine (pepcid), and cromolyn sodium will decrease burn scar itch.

the purpose of this study is to examine the effect of a new approach to treating burn scar itch. in other patient populations experiencing itch, h2 antihistamines and/or topically applied cromolyn sodium have decreased itch. we believe that these medications will reduce itch from burn scars. to test this idea, the investigators will compare two methods of treating itch: 1) recommended oral diphenhydramine (benadryl) with placebo capsule and placebo lotion and 2) recommended oral diphenhydramine (benadryl) with administration of oral famotidine (pepcid) and topically applied cromolyn sodium.

Eligibility criteria:
inclusion criteria: participants must meet all the inclusion criteria in order to be eligible to participate in the study. * participant has provided informed consent in a manner approved by the irb and is willing and able to comply with the trial procedures. * adults: ≥18 to \<80 years of age. * has an itchy burn scar. exclusion criteria: participants meeting any of the exclusion criteria at baseline will be excluded from study participation. * failure to obtain consent or unable to return for follow up assessments. * patient is unable to follow the protocol required assessments. * member of a vulnerable class (e.g., prisoners, pregnant participant, etc.). * any medical condition that, in the opinion of the investigator or physician, would place the participant at increased risk for participation. * concurrent participation in another interventional clinical trial (to avoid confounding factors that may influence outcomes). * history of prior non-compliance or the presence or history of psychiatric condition (including drug or alcohol addiction) that would, in the opinion of the investigator, make it difficult for the participant to comply with the study procedures or follow the investigators instructions. * age \< 18 or ≥ 80 years. * taking one of the following medications: cefuroxime, dasatinib, delavirdine, neratinib, pazopanib, risedronate, or tizanidine. * has a pre-existing inflammatory or itchy skin disease. * is taking an h2 antihistamine for another indication.

Keywords: itch burn diphenhydramine famotidine
huandao conditioning application for allergic rhinitis treatment

Conditions: Allergic Rhinitis

Summary: the goal of this clinical trial is to learn if the huandao conditioning application works to treat allergic rhinitis in adults. it will also learn about the safety of this application. the main questions it aims to answer are: does the huandao conditioning application improve allergic rhinitis symptoms as measured by the rhinitis control assessment test (rcat) and nasal airway resistance tests? what medical problems do participants have when using the huandao conditioning application? researchers will compare the therapeutic version of the application to a placebo version (a look-alike application that contains no therapeutic effect) to see if the huandao conditioning application works to treat allergic rhinitis. participants will: use either the therapeutic or placebo version of the application daily for 1 week in phase 1 take a 2-week break with no application use use the opposite version of the application daily for 1 week in phase 2 visit the clinic at the beginning and end of each phase for checkups and tests complete symptom assessment questionnaires before each application use and 1-2 hours after use be monitored for any adverse reactions throughout the study period

detailed description: allergic rhinitis (ar) is a chronic respiratory condition affecting 15% of the global population. the study investigates a novel mobile application-based intervention utilizing traditional chinese medicine (tcm) meridian theory. study design: randomized, double-blind, placebo-controlled crossover trial two 1-week treatment periods separated by 2-week washout 1:1 randomization to active/placebo app sequence intervention details: therapeutic app: energy-balancing effects based on tcm meridians placebo app: visually identical without therapeutic properties daily 5-10 minute self-administered sessions symptom tracking before and 1-2 hours post-application assessment schedule: baseline: rcat, allergen screening, nasal resistance treatment weeks: daily symptom monitoring, day 4 phone follow-up end of phases: rcat, nasal resistance, adverse events study completion: additional allergen screening target population: 95 participants recruitment via posters at hualien tzu chi hospital expected 70 evaluable subjects for analysis this study aims to evaluate the efficacy and safety of a tcm-based digital therapeutic for ar symptom management.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * rcat score \< 21 * positive allergen screening (\> 0.35 ku/l for house dust, microbial, or pet dander) * capable of operating mobile app and completing follow-up exclusion criteria: * recent diagnosis, active treatment, or recurrence risk of head/neck cancer * current or previous immunotherapy * any condition that may compromise participant safety or interfere with trial assessment per investigator judgment

Keywords: allergic rhinitis
surgical treatment of post-surgical mastectomy pain utilizing the regenerative peripheral nerve interface

Conditions: Post-Mastectomy Chronic Pain Syndrome

Summary: post-mastectomy pain due to nerve injury leads to long-term opioid use and diminished quality-of-life. the investigators on this study will evaluate the regenerative peripheral nerve interface (rpni), a novel surgical approach to neuroma treatment, to improve patient-reported post-mastectomy pain and definitively treat intercostal neuromas after mastectomy.

up to 40% of patients who undergo mastectomy suffer from chronic pain, defined as pain lasting greater than three months. chronic post-mastectomy pain due to nerve injury leads to long-term opioid use and diminished quality-of-life. a novel surgical approach to neuroma treatment, the regenerative peripheral nerve interface (rpni) developed to treat painful neuromas associated with limb amputation has shown significant reductions in patient-reported pain. rpni surgery is now available through michigan medicine's multi-disciplinary peripheral nerve (mdpn) clinic to improve post-mastectomy pain and definitively treat intercostal neuromas following mastectomy. using patient-reported outcomes and clinical data the investigators will evaluate the use of rpni surgery to reduce persistent post- mastectomy pain in women seeking surgical consultation through the plastic surgery or mdpn clinics.

Eligibility criteria:
inclusion criteria: in order to be eligible to participate in this study, a subject must meet all of the following criteria: * reporting post-mastectomy pain at least six months removed from mastectomy or partial mastectomy (lumpectomy). * willing to comply with all study procedures and be available for the duration of the study * fluent in english * women of reproductive potential must use highly effective contraception (specify methods of contraception acceptable for the study, e.g., licensed hormonal methods) and/or willingness to undergo a pregnancy test. exclusion criteria: a potential subject who meets any of the following criteria will be excluded from participation in this study: * previous surgical management for chronic post-mastectomy pain * signs/symptoms which are not suggestive of neuropathic pain based on physical exam at time of consultation. * pregnancy or lactation * men will not be enrolled in this study due to the low prevalence of male mastectomy. * anything that, in the opinion of the investigator, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study.

Keywords: neuroma,outcome-assessment health care, post-mastectomy outcome-assessment health care post-mastectomy neuroma
comparison of orthodontic molar protraction with and without adjunctive surgery

Conditions: Malocclusion

Summary: this study will compare orthodontic molar protraction with and without adjunctive periodontally accelerated osteogenic orthodontic (paoo) surgery prior to orthodontic tooth movement. to the investigators' knowledge, this type of molar retraction in adult patients has not been compared with and without the adjunctive use of paoo for differences in clinical linear tooth movement and patient centered outcomes (discomfort, change in daily activities, satisfaction with esthetic outcomes) in a controlled study.

research data and daily clinical observations reveal that molar protraction (forward movement) in adult patients may be prolonged and ideal outcomes may not be achieved with traditional orthodontic tooth movement. one method for enhancing orthodontic tooth movement is the use of surgical access of the local site to initiate a regional tissue reaction to induce trauma, which leads to a limited inflammatory healing process. this process is also known as regional acceleratory phenomenon (rap), which allows for more rapid bone turnover and has been shown in other protocols to enhance orthodontic tooth movement. while paoo has been shown to rapidly increase tooth movement, to our knowledge, localized use of paoo in combination with molar protraction in adults has not been evaluated in a prospective trial for differences in clinical outcomes (tooth movement time, adverse orthodontic outcomes, periodontal and soft tissue defects) and patient-centered outcomes (pain, swelling, change in daily activities, patient assessment of surgical benefit, and patient-assessed esthetics) in a controlled study.

Eligibility criteria:
inclusion criteria: * english speaking * at least 18 years old * must be a patient of the university of alabama at birmingham (uab) dental school * able to read and understand informed consent document * one or more nonadjacent 1st or 2nd molar teeth that require protraction of ≥ 5 mm in patients undergoing orthodontic tooth movement * presence of periodontally healthy, non-carious neighboring teeth, healthy implants or edentulous ridges on either side of the involved site(s) * no anticipated need for restorative care at the teeth to be treated during the study period. exclusion criteria: * non-english speaking * less than 18 years old * smokers/tobacco users (\>10 cigarettes/day) * patients with systemic pathologies or conditions contraindicating oral surgical procedures or adversely affecting wound healing * presence of active periodontal disease, caries, and/or periapical pathology at teeth to be moved orthodontically * previous orthodontic therapy involving molar protraction of teeth to be treated * previous periodontal surgery at site(s) to be treated

Keywords: orthodontic tooth movement molar protraction periodontally accelerated osteogenic orthodontics patient-centered outcomes
the effects of manual lymphatic drainage on the autonomic nerve system

Conditions: Healthy

Summary: forty healthy women who met the inclusion criteria were included in the study. in the single-blind randomized controlled study, the participants were divided into 3 groups manual lymphatic drainage(mld), sham mld, and control group. after evaluating the demographic information, blood pressure, and heart rate variability (hrv) of the participants, the cold pressure test was applied. immediately after the test, blood pressure and hrv were re-evaluated. the mld group received short neck, abdominal, and lymph node stimulation and right arm mld applications. a sham protocol was applied to the sham mld group. the control group was asked to lie on their back for 10 minutes. after the application, blood pressure and hrv were re-evaluated.

the participants included in the study were randomly divided into 3 groups; manual lymph drainage, sham manual lymph drainage, and a control group in the computer program. participants rested for 5 minutes before the first evaluation. the first evaluation was made after the demographic information of the participant was obtained. within the scope of this evaluation, blood pressure, heart rate, and heart rate variability were evaluated. all assessments were performed on the patient's dominant upper extremity. after the evaluation, cold pressure test was applied to the dominant extremity. a second assessment was made immediately after the test. all of the parameters examined within the scope of the first evaluation were examined for the second time. appropriate treatment was applied to the group to which the participant belonged. after the treatment, the third evaluation was made and the study was terminated. all participants were asked to avoid exercise, caffeine, energy drinks, and heavy meals at least 1 hour before the test. environmental noise, light, and temperature were controlled during the test.

Eligibility criteria:
inclusion criteria: * being over 18 years of age * being voluntary to participate in the study exclusion criteria: * having advanced cardiorespiratory diseases * orthopedic and neurological problems * using medication related to pain * cardiovascular system, having skin disorders that prevent skin contact * having cold urticaria

Keywords: manual lymph drainage autonomic function heart rate variability cold pressure test
butcoins guts: - gut immunological effects of resistant starch and arabinoxylans in subjects with metabolic syndrome

Conditions: Metabolic Syndrome

Summary: dietary fibers including resistent starch, rs, and arabinoxylans, ax, have been shown to have anti-inflammatory effects and to change the composition of the faecal micro flora in the colon. in this unblinded dietary intervention cross-over study 20 subjects with metabolic syndrome are randomized to two types of diet intervention: a low and a high fiber diet. the participants are subjected to endoscopy before and in the end of each intervention.

dietary fibers including resistent starch, rs, and arabinoxylans, ax, have been shown to have anti-inflammatory effects and to change the composition of the faecal micro flora in the colon. in this unblinded dietary intervention cross-over study 20 subjects with metabolic syndrome are subjected to two types of diet intervention: 1. a western style diet, wsd, with a low fiber content and 2. a healthy carbohydrate diet, hcd, a high fiber diet. between the two 4-weeks diet is a wash-out period of four to eight weeks. the participants are subjected to endoscopy with tissue samples before and in the end of each intervention. fecal and blood samples will be collected at the same time. we hypothesize that a high content of resistent starch and arabinoxylans increases colonic butyrate concentration, changes colon's mucosal immune system and the microbiota. a small pilot study will be carried out on 12 healthy volunteers in order to obtain a reference to participants with metabolic syndrome. the healthy volunteers will be subjected to an endoscopy but no dietary intervention.

Eligibility criteria:
inclusion criteria: at least 3 out of 5 following criteria: * central obesity (female \> 80 cm, male \> 94 cm) * hdl cholesterol (female \< 1,03 mmol/l, male \< 1,29 mmol/l) * bloodpressure (\> 130/85 mmhg) * fasting blood glucose \> 5,6 mmol/l exclusion criteria: * diabetes * gastrointestinal disease * serious liver, heart or kidney disease * anticoagulation treatment * anaemia * corticosteroid treatment * waist circumference above 130 cm * alcohol or drug addiction * pregnancy or lactation

Keywords: dietary fibers butyrate short chain fatty acids colon metabolic syndrome
home blood pressure monitoring in kidney transplant recipients

Conditions: Hypertension; Cardiovascular Diseases; Kidney Transplant; Complications

Summary: randomized controlled study of home blood pressure monitoring in kidney transplant recipients.

adult kidney transplant recipients (n=458) will be randomized 1:1 to standard-of-care (soc) or home blood pressure measurement (hbpm). the soc group will target office blood pressure \<130/80 mmhg. the hbpm group will measure bp at home, twice morning and evening for (3-)7 days before routine clinical visits (ideally 28 measurements); the mean value from day 2-7 is used; target home mean bp is \< 125/80 mmhg.

Eligibility criteria:
inclusion criteria: 1. kidney transplant recipient 2. male or female subject ≥ 18 years old 3. any or more of the following at the baseline clinic * conventional office bp ≥130 mmhg systolic and/or ≥ 80 mmhg diastolic * hbpm ≥125 mmhg systolic and/or ≥ 80 mmhg diastolic measured within the last 3 months (see appendix 1 for details on methodology) * daytime ambulatory blood pressure monitoring (abpm) ≥125 mmhg systolic and/or ≥ 80 mmhg diastolic measured within the last 3 months 4. signed informed consent and expected cooperation of the patient for the treatment and follow up. 5. have a national personal identification number and not be expected to emigrate during study 6. enlisted in the norwegian renal registry exclusion criteria: 1. standing systolic bp \< 110 mmhg (to avoid adverse events). measured after one and three minutes of standing. not applicable if unable to stand due to wheelchair use. 2. diagnosed atrial fibrillation (automated monitors not validated) 3. unwilling to self-monitor 4. female participant who is pregnant, lactating or planning pregnancy during the trial (management of essential hypertension in pregnancy is different) 5. arm circumference too large or small to allow accurate bp measurement with available device (22-42 cm). 6. any reason likely limiting adherence to interventions, as judged by the investigator; examples include active alcohol or substance abuse within the last 12 months, significant poor compliance with medications or attendance at clinic visits, residence in a nursing home, dementia, other medical or psychiatric conditions that may interfere with study participation. 7. graft- or life expectancy less than 2 years, as judged by the investigator. 8. current use of ≥ 4 antihypertensive medications 9. more than half of regular appointments planned as remote (e.g. phone or video) consultations. 10. severe white-coat hypertension, e.g. patients already treated solely based on home bp values. 11. multi-organ transplants (e.g. heart, lung, liver), though pancreas or beta-cell islet transplant is allowed.